Charles River Laboratories International (NYSE:CRL) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Charles River Laboratories International (NYSE:CRL) from a buy rating to a hold rating in a research report report published on Saturday morning.

Other analysts have also recently issued reports about the stock. Barclays raised their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a report on Thursday, May 8th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Robert W. Baird raised their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, May 8th. Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Wednesday, May 14th. Finally, Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $171.85.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $157.12 on Friday. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $254.15. The company has a market capitalization of $7.72 billion, a price-to-earnings ratio of -241.72, a price-to-earnings-growth ratio of 5.32 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The firm’s fifty day moving average price is $140.70 and its 200 day moving average price is $152.50.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.27 EPS. On average, research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in CRL. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after purchasing an additional 60,497 shares during the period. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 5.1% in the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock valued at $644,980,000 after purchasing an additional 208,586 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Charles River Laboratories International by 8.0% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock valued at $293,555,000 after purchasing an additional 144,732 shares during the period. Geode Capital Management LLC raised its position in shares of Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after purchasing an additional 14,787 shares during the period. Finally, Invesco Ltd. raised its position in shares of Charles River Laboratories International by 7.2% in the first quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company’s stock valued at $166,830,000 after purchasing an additional 74,178 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).